In 2025, artificial intelligence (AI)—including Generative AI (GenAI)—has emerged as a strategic differentiator for medtech firms worldwide. Companies could capture $14 billion to $55 billion annually in productivity gains, with an additional $50 billion in revenue growth from AI-driven product and service innovation.¹ In addition, GenAI adoption is accelerating. The segment of life sciences companies budgeting over $5 million for GenAI rose from 20% in 2024 to 32% in 2025.¹

Why This Is Important

In a survey by Deloitte of 85 medtech leaders, it was revealed 42% report AI-driven benefits in product development (Table 1), and GenAI could reduce costs by 6% to 12% of total revenue over two to three years.² With typical large company medtech revenue accounting for billions of dollars, this translates into significant annual cost savings—enough to fund major R&D initiatives or M&A activity.

These quantitative signals firmly establish 2025 as a tipping point: AI is no longer experimental; it’s reshaping medtech across R&D, commercial, and operational domains.

Strategic and Financial Impact on Medtech

It is projected the combined value from AI in medtech could range between $64 billion and $105 billion annually, split between $14-55 billion in efficiency-related gains such as faster R&D, manufacturing, and/or compliance.¹ An additional $50 billion or more in entirely new revenue streams in smart devices, predictive maintenance, and value-based services could also be created. 

Life Science Investment Trends in GenAI

Budget increases of greater than $10 million for GenAI rose from 13% in 2024 to 20% in 2025. Life science companies spending $5-$10 million increased from 7% to 12% of the total, while the segment spending <$1 million dropped from 43% to 35% (Table 2).¹ This shift underscores the number of companies scaling from pilot projects to enterprise-grade investments.

In addition, in 2025, two-thirds of medtech companies have begun implementation of GenAI, with greater than 50% still in the pilot phase, but more than 20% in full-scale rollout.^1,2 Fifteen percent of medtech companies report direct positive P&L impact from GenAI, and globally, approximately 40% of health executives report “significant-to-moderate” ROI from GenAI.^3,4 This signals a first wave of companies transitioning from experimentation to profitable deployment.

AI Applications in Medtech

In labeling and documentation, AI improves speed by 20% to 30%, compressing review cycles.¹ AI shortens cycle times and enables use of multimodal data in clinical trial design.²

In sales, a 1.5x to 2x increase in leads, a 50% higher proposal conversion, and up to 10% revenue increase for early adopters has been reported.⁵ Combining this with improved conversion rates, ROI could exceed 10x the marketing investment. Forty percent of medtech firms are deploying AI-powered customer service, and 33% are using AI in marketing and legal reviews.¹

In operations and supply chain, 30% use AI forecasting in inventory and procurement, and 20% apply AI in contract analytics.¹ The cost savings for AI-powered invoice and contract management drove 1% to 4% savings, and negotiation assistants added another 1% to 4%.¹

Thirty-five percent of medtech firms report deriving benefits in IT & cybersecurity.² While not quantified as clearly, this typically translates into cost avoidance from fewer breaches and more efficient infrastructure.

Organizational Readiness and Barriers

In a late 2024, a survey of 100+ life sciences execs (including medtech) found that 100% were piloting GenAI and 32% were scaling across functions.¹ Barriers include a lack of enterprise GenAI strategy (75%) and talent gaps, especially prompt engineers (94% lacked role mapping). Also reported was change management underinvestment, which is expensive, requiring $5 in change for every $1 in tech and governance/risk blind spots. Thirty-five percent reported minimal engagement (<10 hours) with risk teams. To scale, Deloitte argues for a “string-of-pearls” approach: integrating multiple AI use cases with data strategy, digital tools, and COEs. This is necessary to unlock the full estimated 6% to 12% cost gain of AI.²

Global Societal and Policy Impact

A study via MedTech Europe estimates that AI-enabled medtech in Europe could save €200 billion annually, protect 400,000 lives each year, and free up 1.8 billion working hours, equivalent to 500,000 full-time professionals.⁶ If these same metrics scale across North America and Asia-Pacific, global workforce relief and cost avoidance could reach $500 billion annually.

Globally, the productivity of AI in healthcare is expected to grow from $27.7 billion (2023) to nearly $491 billion by 2032 at a robust CAGR of approximately 39%.³ Though not medtech-specific, this reflects medtech’s digital-forward role.

Risks and Ethical Considerations

Regulatory readiness is fragmented. New LLM-focused regulatory science frameworks are emerging.¹ However, bias, hallucinations, and IP concerns are real, and it is reported that 35% of companies barely engage risk teams.² Transparency and clinician acceptance of AI remain critical. Guardrails are needed to embed ethics from design to deployment. For executives, investing in governance structures, bias mitigation, validation, and change management are non-negotiable.

Competitive Positioning and Market Dynamics

First movers in medtech (top ~15%) are realizing P&L benefits. The mid-tier organizations (~50%) are scaling; late adopters risk irrelevance. Private equity, PE-backed firms, and digitally native players are adopting AI aggressively and forming integrated service platforms. This is a competitive threat to traditional firms with slower digital agendas. Cross-industry partnerships (e.g., with cloud providers, AI startups) may be essential to accelerate deployment.

Here is a benchmarking tip. If you’re at the median, expect 20% pilot adoption and <5% ROI realization. Your goal is to reach peer leadership; >50% in pilots, 20%+ P&L impact, with centralized AI governance and cross-functional implementation.

Recommendations for Medtech Leaders

1. Start scaling now—Shift from isolated pilots to enterprise-wide GenAI adoption.
2. Track ROI aggressively—Align AI KPIs with revenue growth and cost reduction.
3. Build governance and upskill teams—Prompt engineering and risk oversight are critical.
4. Explore M&A and partnerships—AI capability is now a deal multiplier.
5. Champion ethical, explainable AI—To maintain trust and stay compliant globally.

The Medi-Vantage Perspective

By mid-2025, AI has crossed the Rubicon from experimentation to business core in medtech. Early ROI is clear. Top-performing firms are capturing measurable efficiency, boosting innovation, and positioning for long-term competitive advantage. Executives who move decisively to institutionalize, govern, and scale can unlock millions in savings, multi-million-dollar top-line growth, and strategic resilience against digitally savvy disruptors.

By the end of 2025, the winners in medtech will be those who have invested not just in AI technology, but also in strategy, talent, process integration, governance, and culture. Successful early adopters are already delivering hundreds of millions in financial impact—and broader system effects signal a future where AI-enabled devices are standard, patient care is more efficient, and medtech plays a central role in global healthcare transformation.

References

1. tinyurl.com/mpo250901
2. tinyurl.com/mpo250902
3. tinyurl.com/mpo250903
4. tinyurl.com/mpo250904
5. tinyurl.com/mpo250905
6. tinyurl.com/mpo250906

MORE FROM THIS AUTHOR: Six Steps to Implementing a Medical Device Business Turnaround

Maria Shepherd has more than 20 years of experience in marketing in small startups and top-tier companies. She founded Medi-Vantage, which provides marketing and business strategy for the medtech industry. She can be reached at mshepherd@medi-vantage.com. Visit her website at www.medi-vantage.com.